CNTB(CNTB)
CNTB
ANALYST COVERAGE5 analysts
BUY
▲ +176.6%upside to target
L $4.00
Med $6.50consensus
H $9.00Key MetricsTTM
Market Cap$132.83M
Revenue TTM$24.86M
Net Income TTM-$22.07M
Free Cash Flow-$48.46M
Gross Margin100.0%
Operating Margin-60312.5%
Net Margin-58350.0%
Return on Equity-49.4%
Return on Assets-49.9%
Debt / Equity0.02
Current Ratio3.74
EPS TTM$-0.50
PRICE
Prev Close
2.36
Open
2.38
Day Range2.32 – 2.45
2.32
2.45
52W Range0.72 – 3.82
0.72
3.82
53% of range
VOLUME & SIZE
Avg Volume
257.0K
FUNDAMENTALS
P/E Ratio
-2.0x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
0.57
Low vol
TECHNICAL
RSI (14)
43
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 116 days
Sep 15
CNTB News
About
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from its T cell-driven research. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), which is a validated target for the treatment of several inflammatory diseases such as atopic dermatitis (AD) and asthma. Its second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1).
Industry
Research and Development in Biotechnology
Website
Sean T. RistineVice President of Human Resources
Kimberly J. ManhardExecutive Vice President & Chief Development Officer
Lisa PerazaSenior Vice President of Finance
Barry D. QuartChief Executive Officer & Director
Lei SunVice President of Biologics & Head of CMC
Srikanth PendyalaSenior Vice President of Clinical Development(Consultant)
David L. SzekeresPresident
Jeff CohnGeneral Counsel & Corporate Secretary